ATE509032T1 - Chimerizierte gm-csf antikörper - Google Patents

Chimerizierte gm-csf antikörper

Info

Publication number
ATE509032T1
ATE509032T1 AT03713430T AT03713430T ATE509032T1 AT E509032 T1 ATE509032 T1 AT E509032T1 AT 03713430 T AT03713430 T AT 03713430T AT 03713430 T AT03713430 T AT 03713430T AT E509032 T1 ATE509032 T1 AT E509032T1
Authority
AT
Austria
Prior art keywords
antibodies
chimerized
disclosed
well
fusion proteins
Prior art date
Application number
AT03713430T
Other languages
English (en)
Inventor
Christoph Renner
Andrew Scott
Antony Burgess
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Application granted granted Critical
Publication of ATE509032T1 publication Critical patent/ATE509032T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03713430T 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper ATE509032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35583802P 2002-02-13 2002-02-13
PCT/US2003/004185 WO2003068920A2 (en) 2002-02-13 2003-02-12 Humanized gm-csf antibodies

Publications (1)

Publication Number Publication Date
ATE509032T1 true ATE509032T1 (de) 2011-05-15

Family

ID=27734567

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Country Status (8)

Country Link
US (5) US7714113B2 (de)
EP (2) EP1530580B1 (de)
JP (1) JP2006500905A (de)
AT (2) ATE444308T1 (de)
AU (2) AU2003217386B2 (de)
DE (1) DE60329489D1 (de)
ES (1) ES2365606T3 (de)
WO (2) WO2003068924A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
ATE444308T1 (de) * 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
ATE537842T1 (de) 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP1763367A2 (de) * 2004-07-02 2007-03-21 Wilex AG Verbesserte adjuvans therapie für g250 exprimierende tumore
MX2007012569A (es) * 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
JP2010527939A (ja) * 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) * 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
CA2711763A1 (en) * 2008-01-15 2009-07-23 Kalobios Pharmaceuticals, Inc. Methods of treating bone-loss disorders using a gm-csf antagonist
WO2009126659A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
KR101706789B1 (ko) * 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
ES2533493T3 (es) * 2008-08-20 2015-04-10 Probiodrug Ag Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
EP3381471B1 (de) 2008-12-22 2024-03-20 The University of Melbourne Schmerzbehandlung
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
KR20160144416A (ko) * 2014-04-04 2016-12-16 오토텔릭 엘엘씨 파클리탁셀의 약물동태-유도된 투여를 위해 혈장 중의 파클리탁셀 농도를 모니터링하는 방법, 장치 및 시약
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CN111757744A (zh) 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US12344646B2 (en) 2018-12-13 2025-07-01 Bang DING Antibody-TNF α fusion protein and its preparation and applications
WO2021188409A1 (en) * 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
FR2723462B1 (fr) 1994-08-02 1996-09-06 Thomson Lcd Procede d'adressage optimise d'ecran a cristaux liquides et dispositif pour sa mise en oeuvre
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
JP2003525061A (ja) * 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ATE444308T1 (de) * 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Also Published As

Publication number Publication date
WO2003068920A8 (en) 2004-07-29
US20100167395A1 (en) 2010-07-01
US20060045876A1 (en) 2006-03-02
WO2003068920A2 (en) 2003-08-21
US7381801B2 (en) 2008-06-03
US20120029172A1 (en) 2012-02-02
ES2365606T3 (es) 2011-10-07
EP1530580B1 (de) 2011-05-11
US7714113B2 (en) 2010-05-11
EP1507859A2 (de) 2005-02-23
EP1530580A2 (de) 2005-05-18
US20040053365A1 (en) 2004-03-18
EP1507859B1 (de) 2009-09-30
DE60329489D1 (de) 2009-11-12
WO2003068920A3 (en) 2004-07-01
AU2003217386B2 (en) 2008-06-26
US20090259027A1 (en) 2009-10-15
EP1530580A4 (de) 2006-02-01
AU2003215188A8 (en) 2003-09-04
WO2003068920A9 (en) 2004-06-03
AU2003215188A1 (en) 2003-09-04
EP1507859A4 (de) 2007-05-30
US7897743B2 (en) 2011-03-01
WO2003068924A3 (en) 2004-12-29
WO2003068924A2 (en) 2003-08-21
JP2006500905A (ja) 2006-01-12
AU2003217386A1 (en) 2003-09-04
ATE444308T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
WO2005012493A3 (en) Anti-cd19 antibodies
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1641483T3 (da) Fusionsproteiner
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CY1116506T1 (el) Αντισωματα εναντι masp-2
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
MY154009A (en) Anti-alpha v beta 6 antibodies
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
TW200510459A (en) RG1 antibodies and uses thereof
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
WO2004093808A3 (en) Novel tumor-associated antigens
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2001004143A3 (en) Prostase vaccine
DE60130804D1 (de) Antagonistischer antikörper gegen pro842
WO2005047456A3 (en) Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties